HYDROCODONE BITARTRATE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Alvogen	HYDROCODONE BITARTRATE	hydrocodone bitartrate	CAPSULE, EXTENDED RELEASE;ORAL	206986	ANDA	Alvogen Inc.	47781-409-60	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (47781-409-60)	2020-01-21
Alvogen	HYDROCODONE BITARTRATE	hydrocodone bitartrate	CAPSULE, EXTENDED RELEASE;ORAL	206986	ANDA	Alvogen Inc.	47781-410-60	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (47781-410-60)	2020-01-21
Alvogen	HYDROCODONE BITARTRATE	hydrocodone bitartrate	CAPSULE, EXTENDED RELEASE;ORAL	206986	ANDA	Alvogen Inc.	47781-411-60	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (47781-411-60)	2020-01-21
Alvogen	HYDROCODONE BITARTRATE	hydrocodone bitartrate	CAPSULE, EXTENDED RELEASE;ORAL	206986	ANDA	Alvogen Inc.	47781-412-60	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (47781-412-60)	2020-01-21
Alvogen	HYDROCODONE BITARTRATE	hydrocodone bitartrate	CAPSULE, EXTENDED RELEASE;ORAL	206986	ANDA	Alvogen Inc.	47781-413-60	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (47781-413-60)	2020-01-21
Alvogen	HYDROCODONE BITARTRATE	hydrocodone bitartrate	CAPSULE, EXTENDED RELEASE;ORAL	206986	ANDA	Alvogen Inc.	47781-414-60	60 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (47781-414-60)	2020-01-21
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report details the primary global suppliers of hydrocodone bitartrate, a critical active pharmaceutical ingredient (API) for pain management medications. The analysis covers key manufacturers, their geographical distribution, and market trends impacting supply chain stability.

Who are the Main Global Producers of Hydrocodone Bitartrate API?

The global production of hydrocodone bitartrate API is concentrated among a limited number of manufacturers, primarily located in North America and India. These companies operate under stringent regulatory oversight from bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Key Hydrocodone Bitartrate API Manufacturers:

Mallinckrodt Pharmaceuticals: A significant player in the opioid API market, with manufacturing facilities historically based in the United States. Mallinckrodt has been a long-standing supplier to the North American pharmaceutical industry. The company has faced significant legal challenges related to its role in the opioid crisis, impacting its operational focus and potentially its API supply capacity.
Amneal Pharmaceuticals: Through its acquisition of specialty pharmaceutical assets, Amneal has become a notable supplier of various APIs, including controlled substances. Their manufacturing operations are largely based in the United States.
Sun Pharmaceutical Industries Ltd.: A major Indian pharmaceutical company, Sun Pharma produces a wide range of APIs. While not exclusively focused on opioids, they have the capacity and regulatory approvals to manufacture hydrocodone bitartrate for global markets. Their production often leverages economies of scale typical of Indian API manufacturers.
Dr. Reddy's Laboratories: Another prominent Indian pharmaceutical company, Dr. Reddy's is a significant global API supplier across multiple therapeutic areas. They possess the necessary infrastructure and regulatory compliance for controlled substance API manufacturing, including hydrocodone bitartrate.
Actavis (now part of AbbVie): Historically, Actavis was a key supplier of opioid APIs. Following its acquisition by AbbVie, the integration of its manufacturing capabilities has influenced the broader market for these substances. Operations are distributed across several regions.

Geographical Distribution of Production:

The concentration of production in specific regions is driven by regulatory frameworks, manufacturing expertise, and historical market access.

United States: Houses key manufacturers like Mallinckrodt and Amneal. These facilities operate under strict DEA (Drug Enforcement Administration) quotas and FDA oversight.
India: Emerges as a significant global API hub, with companies like Sun Pharma and Dr. Reddy's leveraging advanced chemical synthesis capabilities and competitive cost structures. Indian manufacturers often serve both domestic and international markets, including the U.S. and Europe.

What are the Regulatory Hurdles for Hydrocodone Bitartrate API Production and Distribution?

Hydrocodone bitartrate is classified as a Schedule II controlled substance in the United States under the Controlled Substances Act (CSA). This classification imposes rigorous controls on its manufacturing, distribution, and dispensing. Similar stringent regulations exist in other major markets.

Key Regulatory Controls:

DEA Quotas: The U.S. Drug Enforcement Administration (DEA) sets annual aggregate production quotas for Schedule II controlled substances, including hydrocodone bitartrate. Manufacturers must apply for and adhere to these quotas, which limit the total amount of API that can be produced and imported into the U.S. each year. These quotas are subject to adjustments based on public health needs and diversion control. For example, the DEA's proposed 2024 aggregate production quota for hydrocodone was 6,678 kgs [1]. This represents a decrease from previous years, reflecting a trend of reducing overall opioid production.
FDA Oversight: The FDA monitors manufacturing processes for API quality, purity, and consistency. Manufacturers must comply with current Good Manufacturing Practices (cGMP) and undergo regular inspections. For imported APIs, the FDA reviews Drug Master Files (DMFs) and conducts site inspections.
Import/Export Controls: The importation and exportation of hydrocodone bitartrate API are subject to strict permits and declarations to prevent diversion into illicit channels. The DEA scrutinizes import and export applications for controlled substances.
International Narcotics Control Board (IN সার্ব) / UN Conventions: Global trade in hydrocodone bitartrate is governed by international treaties, such as the Single Convention on Narcotic Drugs, 1961, as amended by the 1972 Protocol. The IN সার্ব monitors compliance with these conventions.
State-Level Regulations: In addition to federal regulations, individual U.S. states may have their own laws pertaining to the manufacturing, handling, and security of controlled substances.

The complex and evolving regulatory landscape directly impacts the cost of compliance, production capacity, and supply chain predictability for hydrocodone bitartrate API.

How Do Supply Chain Disruptions Affect Hydrocodone Bitartrate Availability?

The hydrocodone bitartrate supply chain, like many pharmaceutical supply chains, is vulnerable to various disruptions. The controlled nature of the API amplifies the impact of these events.

Potential Causes of Disruption:

Regulatory Changes: Modifications to DEA quotas, stricter import/export rules, or new cGMP requirements can immediately constrain supply or necessitate costly process adjustments for manufacturers. For instance, unexpected reductions in DEA quotas can lead to API shortages for finished drug manufacturers.
Raw Material Shortages: The synthesis of hydrocodone bitartrate relies on precursor chemicals. Disruptions in the supply of these upstream raw materials, often due to geopolitical instability, environmental events, or production issues at chemical suppliers, can halt API production.
Manufacturing Issues: Equipment failures, contamination incidents, or labor disputes at API manufacturing sites can lead to production downtime and reduced output. The specialized nature of controlled substance manufacturing means that restarting production after an incident can be lengthy and complex.
Geopolitical Factors: Trade disputes, sanctions, or political instability in regions where key raw materials or API manufacturing facilities are located can impede the flow of goods.
Logistical Challenges: Transportation delays, port congestion, or increased shipping costs can impact the timely delivery of APIs to finished dosage form manufacturers. The secure transport of controlled substances requires specialized logistics, adding another layer of complexity and cost.
Legal and Compliance Issues: Investigations or enforcement actions against API manufacturers for regulatory violations can lead to production halts or facility shutdowns, directly impacting market supply.

Impact on Pharmaceutical Companies:

For pharmaceutical companies relying on hydrocodone bitartrate for their pain relief medications, supply disruptions can result in:

Production Delays: Inability to secure sufficient API halts the manufacturing of finished drug products.
Inventory Depletion: Existing stock of finished medications dwindles, potentially leading to stock-outs.
Increased Costs: Companies may face higher API prices due to scarcity, or incur additional costs for expedited shipping or sourcing from alternative, potentially more expensive, suppliers.
Market Share Loss: Failure to meet patient demand can result in lost sales and market share to competitors with more stable supply chains.

What are the Market Trends Influencing Hydrocodone Bitartrate API Supply?

Several evolving trends are shaping the market for hydrocodone bitartrate API, influencing both supply and demand dynamics.

Key Market Trends:

Declining Opioid Prescribing: Public health initiatives, increased awareness of opioid addiction, and the availability of alternative pain management therapies have led to a sustained decrease in the overall prescribing of opioid-based medications, including those containing hydrocodone. This trend directly reduces the demand for hydrocodone bitartrate API from finished drug manufacturers.
Increased Regulatory Scrutiny and Quota Reductions: In response to the opioid crisis, regulatory bodies globally, particularly the DEA in the U.S., have systematically reduced aggregate production quotas for opioid APIs. For example, the DEA's proposed quota for hydrocodone for 2024 is significantly lower than historical levels. This policy directly constrains the available API supply.
Shift Towards Alternative Pain Management: The development and adoption of non-opioid analgesics, as well as non-pharmacological pain management strategies (e.g., physical therapy, neuromodulation), are diminishing the market share of opioid-based treatments.
Consolidation in the Pharmaceutical Industry: Mergers and acquisitions can lead to changes in manufacturing strategies and supplier relationships. Companies may rationalize API sourcing, potentially impacting the market positions of certain suppliers.
Focus on Supply Chain Resilience: Pharmaceutical companies are increasingly prioritizing supply chain resilience. This involves diversifying API suppliers, increasing inventory levels, and conducting more robust risk assessments of their supply chains. However, the tightly regulated nature of controlled substances limits the ease of supplier diversification.
Generic Competition: While the demand for hydrocodone bitartrate is declining, the market for generic hydrocodone-based formulations remains, contributing to a consistent, albeit smaller, demand for the API from generic manufacturers.

These trends collectively point towards a contracting market for hydrocodone bitartrate API, characterized by reduced production quotas and decreasing demand from finished drug manufacturers.

What are the Implications for R&D and Investment in Hydrocodone Bitartrate?

The current market dynamics for hydrocodone bitartrate API present significant challenges and limited opportunities for research and development (R&D) and investment.

R&D Implications:

Limited Scope for New Product Development: Given the declining prescribing trends and regulatory pressures, there is minimal incentive for R&D focused on developing new hydrocodone bitartrate-based formulations or novel applications. Investment in this area is unlikely to yield significant returns.
Focus on Process Optimization and Compliance: For existing hydrocodone bitartrate API manufacturers, R&D efforts are likely concentrated on process optimization to improve yields, reduce costs, and ensure continuous compliance with evolving cGMP and regulatory requirements. This is primarily for maintaining existing market share rather than expansion.
Research into Alternatives: The primary R&D focus related to pain management lies in developing non-opioid analgesics and novel pain therapies. Pharmaceutical companies are channeling resources away from opioid-based research towards these alternatives.

Investment Implications:

Declining Investment Appeal: The market for hydrocodone bitartrate API is characterized by shrinking demand and stringent regulatory controls. This makes it an unattractive sector for new investment, particularly for companies seeking high growth.
Focus on Established, Compliant Suppliers: Any investment activity would likely be directed towards established API manufacturers with a proven track record of regulatory compliance and secure supply chains. However, the controlled substance nature and quota limitations restrict market entry.
Risk Mitigation for Existing Holdings: For entities holding investments in companies involved in hydrocodone bitartrate API production, the focus will be on risk mitigation. This includes assessing the long-term viability of these operations in the face of declining demand and potential further regulatory tightening, as well as managing reputational risks associated with opioid manufacturing.
Potential for M&A Among Niche Players: While broad market investment is unlikely, there could be niche consolidation opportunities among existing, compliant manufacturers looking to streamline operations or exit the market. This is driven more by strategic divestment than growth investment.

The overall outlook for hydrocodone bitartrate API points away from expansion and towards a managed decline, with R&D and investment strategically shifting to alternative therapeutic areas.

Key Takeaways

Global hydrocodone bitartrate API production is concentrated among a few manufacturers in North America and India.
Strict regulatory oversight from bodies like the DEA and FDA, including aggregate production quotas, dictates API availability.
The supply chain is vulnerable to regulatory changes, raw material issues, and logistical challenges.
Market trends indicate declining demand due to reduced opioid prescribing and a shift towards alternative pain management.
R&D and investment in hydrocodone bitartrate API are limited, with focus shifting to compliance and alternative therapies.

Frequently Asked Questions

What is the primary function of hydrocodone bitartrate API? Hydrocodone bitartrate API is used in the manufacturing of prescription medications for moderate to moderately severe pain relief.
How do DEA quotas affect the supply of hydrocodone bitartrate? DEA quotas directly limit the total amount of hydrocodone bitartrate that can be legally manufactured or imported into the United States each year, thereby controlling its availability to pharmaceutical companies.
Are there significant differences in quality standards between U.S. and Indian hydrocodone bitartrate API manufacturers? Both U.S. and Indian manufacturers supplying to regulated markets like the U.S. and Europe must adhere to stringent current Good Manufacturing Practices (cGMP) standards as enforced by regulatory bodies such as the FDA and EMA. Quality is assessed through inspections and review of Drug Master Files.
What are the main challenges faced by hydrocodone bitartrate API suppliers in the current market? Suppliers face challenges including declining demand due to reduced opioid prescribing, increasingly stringent regulatory quotas, and public health pressures related to opioid misuse.
Can pharmaceutical companies easily switch between different hydrocodone bitartrate API suppliers? Switching suppliers requires rigorous validation processes to ensure the API from the new supplier meets all quality and consistency requirements, as well as regulatory approval for changes to the drug product’s manufacturing. This process can be time-consuming and costly, especially for controlled substances.

Citations

[1] U.S. Drug Enforcement Administration. (2023). Final rule: Adjustment of aggregate production quotas—hydrocodone. Federal Register, 88(209), 73172-73174. https://www.federalregister.gov/documents/2023/10/30/2023-23954/final-rule-adjustment-of-aggregate-production-quotas-hydrocodone

Suppliers and packagers for generic pharmaceutical drug: HYDROCODONE BITARTRATE